MTOR and activated PI3K-delta syndrome: Functional testing on T and B cells in APDS patients demonstrated increased AKT and S6 phosphorylation as a result of augmented mTOR signaling (20), thereby supporting the use of mTOR-targeted therapy to control the disease (28).